Pharmafile Logo
Pharmafocus logo
Advanced Search

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024
Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …

News

ViroCell Biologics signs Master Services Agreement with NCI-designated cancer centre

July 23, 2024
Business Services Cancer, Oncology, ViroCell Biologics, agreement

ViroCell Biologics has announced that it has signed a five-year Master Services Agreement (MSA) with a prominent US-based NCI-designated cancer …

News

60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study

July 22, 2024
Medical Communications 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials

60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites …

News

Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM

July 22, 2024
Research and Development Altuviiio, Haematology, Sanofi, haemophilia

Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …

News

GSK’s application for Blenrep for MM treatment accepted for EMA review

July 19, 2024
Medical Communications Blenrep, EMA, GSK, Oncology

GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …

News

Brainomix and Boehringer Ingelheim enter strategic partnership

July 19, 2024
Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership

Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …

News

FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review

July 18, 2024
Medical Communications Atara Biotherapeutics, FDA, Virology, priority review

Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License …

News

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application

July 18, 2024
Medical Communications China, Everest Medicines, NMPA, Nephrology

Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …

News

Loci Orthopaedics announces €12.8m series A financing

July 17, 2024
Business Services Financing, Musculo-skeletal disorder, investment, loci orthopaedics

Loci Orthopaedics has announced the successful closing of an oversubscribed €12.8m series A financing, which was led by new investors …

News

Renalys Pharma closes ¥6bn series A financing for kidney disease treatments in Asia

July 17, 2024
Business Services Financing, Nephrology, kidney disease, renalys Pharma

Renalys Pharma has announced that it has completed ¥6bn series A financing, which was led by Catalys Pacific and SR …

News

Camurus shares phase 3 results from ACROINNOVA 2 study

July 16, 2024
Research and Development Camurus, Pharmacy, acromegaly, clinical trial, injection

Camurus has announced positive results from its 52-week phase 3 open-label ACROINNOVA 2 study, which assessed the safety and efficacy …

News

NICE recommends digital tech for ADHD diagnosis in children and young people

July 16, 2024
Medical Communications ADHD, Diagnostics, NICE

The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …

News

AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding

July 15, 2024
Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding

Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …

News
heart-2372134_640

ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models

July 15, 2024
Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug

Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …

News
body scan

Pfizer selects once-daily obesity drug for advancement

July 12, 2024
Research and Development Obesity, Pfizer Inc, clinical trials, obesity

Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …

News
lung_cancer_on_chest_x-ray

Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection

July 12, 2024
Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer

Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …

News

Aspect Biosystems announces partnership with governments of Canada and British Columbia

July 11, 2024
Business Services Aspect Biosciences, Pharmacy, government, investment

Aspect Biosystems has announced that it has entered into an agreement with the governments of Canada and British Columbia, under …

News

Biophytis gains IND approval from FDA for obesity study

July 11, 2024
Medical Communications Biophytis, IND, Obesity, clinical trial, obesity

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …

News

Pharmaxo acquired by Icon Group in strategic partnership

July 10, 2024
Business Services Oncology, Pharmaxo, acquisition, strategic parnership

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global …

News

Certara to acquire Chemaxon for drug discovery portfolio

July 10, 2024
Business Services Certara, Chemaxon, Pharmacy, acquisition, drug discovery

Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon. The deal …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025